Intravenous (IV) Iron Drugs Market Size, Share and Analysis by Type (Iron Sucrose, Dextran, Ferric Carboxyl Maltose, Ferric Gluconate), By Application (Gynecology, Oncology, Nephrology), By End User (Hospitals, Ambulatory Surgery Centers, Homecare Settings) and Regional Forecast, 2026-2034

The global intravenousiron drugs market size was valued at USD 3.68 billion in 2025. The market is projected to grow from USD 4.02 billion in 2026 to USD 8.16 billion by 2034, exhibiting a CAGR of 9.26% during the forecast period.

Iron is part of hemoglobin, and carries the oxygen in the blood and also enables the production of red blood cells. When an individual is deficient in iron requirements of the body, the diagnosed condition is known as anemia. Some of the symptoms of anemia include loss of energy and fatigue, unusually rapid heartbeat while exercising, difficulty in concentration, pale skin and dizziness, insomnia and cramps. According to a survey conducted by the Vitamin and Mineral Nutrition Information System in 2017, approximetly 30% women and children in developing countries suffering from anemia.

According to the American Society of Hematology, anemia is the most common blood disorder in the U.S. and affects more than 3 million individuals in the U.S. Increasing prevalence of anemia, increasing prevalence of associated diseases leading to anemia are some of the factors propelling the growth of the global intravenous (IV) iron drugs market.

To gain extensive insights into the market, Download for Customization

Additionally, increasing research and development in intravenous iron, rising demand for preventive medical care, and expanding treatment options for anemia are some of the factors boosting the global intravenous (IV) iron drugs market growth.

The factors limiting the growth of the global intravenous (IV) iron drugs market are the associated side effects of the intravenous (IV) iron drugs and specific safety issues associated with the procedure. This combined with lack of adherence to treatment among patient population especially in emerging countries, are major factors restraining the growth of the global market.

Key Players Covered

The major companies covered in the global intravenous (IV) iron drugs market report Daiichi Sankyo, Inc., Sanofi, AMAG Pharmaceuticals, Inc., Allergan, Nippon Shinyaku Co., Lt, and Pharmacosmos A/S., and others.

SEGMENTATION

As per the current intravenous (IV) iron drugs market trends, increased use and intake of IV iron drugs among chronic kidney disease patients has led to the nephrology segment accounting for largest market share.

Key Insights

• Pipeline Analysis
• Recent Advancements in Global Intravenous (IV) Iron Drugs Market
• Key mergers and acquisitions

Regional Analysis

The global intravenous (IV) iron drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the intravenous (IV) iron drugs market in 2018 due to a number of factors such as the increasing prevalence of anemia, increasing incidence for associated diseases such as celiac disease and inflammatory bowel disease, high healthcare expenditure, access to advanced intravenous (IV) iron drugs due to advancements in research & development and rising demand for preventive medical care. Asia Pacific is projected to be the fastest emerging market due to increasing awareness and incidence of anemia, increasing access to intravenous (IV) iron drugs, rising prevalence of acute and severe diseases such as inflammatory bowel disease. Latin America and the Middle East and Africa are anticipated to grow at a relatively lower CAGR during the forecast period.

Intravenous (IV) Iron Drugs Industry Developments

• In May 2019, Rockwell Medical, Inc., submitted new Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the Intravenous (I.V.) formulation of Triferic
• In April 2018, AMAG Pharmaceuticals received FDA approval for supplemental new drug application for ferumoxytol injection to include all eligible adults with iron-deficiency anemia (IDA) who cannot tolerate or have not responded to oral iron.